Good afternoon, Madam Chair and members of the committee. Thank you for the opportunity to speak to you today about antimicrobial resistance, or AMR for short.
My name is Dao Nguyen, and I speak to you as a physician working at McGill University's main teaching hospital, as a professor of medicine, as a microbiology researcher who studies difficult-to-treat bacterial infections and as the founder-director of the McGill AMR Centre and a new AMR Québec network, where I lead efforts to structure and mobilize a multisectoral AMR research ecosystem of over 150 researchers in Quebec. We engage with government, private partners and public partners across the human, animal and environmental health sectors.
As this is the fifth session on AMR of this standing committee, you have undoubtedly already heard many statistics about AMR, which I will not repeat. The pan-Canadian action plan, the AMR report by the Council of Canadian Academies and numerous other global reports all provide the data to tell us that AMR is a silent pandemic that threatens the safety and health of our population, our health care system and beyond.
However, what I would like to bring to your attention to today are a few current realities about AMR and human health care in Canada.
First, antibiotics are currently used by nearly every type of doctor, even dentists and pharmacists. They are used not only to treat infections but also to prevent infection complications that arise from treatments like chemotherapy and from interventions like surgery. However, with the rise of drug-resistant bacteria, particularly those resistant to carbapenems, powerful antibiotics of last resort, the options for effective and safe antibiotics are shrinking and are sometimes not available at all.
Second, to treat the right patient with the right drug at the right time, a health care provider needs to have timely diagnostic information. Are they treating a bacterial infection? What bacteria is it? Is it drug-resistant? With the currently available diagnostic tests, it likely will take three to five days to get an answer, if at all. Antibiotics are most often used empirically, which is medical jargon to say “by guesswork”.
Third, taking carbapenem-resistant enterobacterales as an example, these very concerning drug-resistant bacteria have already reached levels of 70% to 80% in certain regions of the world today, as we speak. In Canada, although the rates are still low in comparison, they are rising exponentially despite the surveillance, infection-prevention and control programs already in place.
The AMR crisis is knocking at our doors, and we are not equipped to handle it. In fact, it is not enough to do more of the same. We are in dire need of new solutions.
We need to preserve existing antibiotics, but we also need new treatments. We need faster and accessible diagnostic tests in order to prescribe the most appropriate and effective antibiotics. We need surveillance systems that are more comprehensive and timely enough to track where drug-resistant bacteria spread across the human, animal and environmental continuum, and to guide action.
I would therefore highlight that research and innovations done in a collaborative and strategic manner are essential to addressing the AMR crisis.
First, academic research is an important source of innovations, from discoveries to spinoff companies. Researchers are critical for understanding what the AMR problems are and for guiding effective interventions. Canadian researchers have notable strengths and expertise upon which to build.
Second, we can build teams that transcend disciplines and use cutting-edge approaches to come up with better and more creative solutions.
Third, members of the academic community are important conduits for mobilizing the AMR ecosystem, one that is rich in expertise but highly complex and fragmented across sectors and disciplines.
What do I think is lacking and what do we need to do?
To deal with the AMR crisis, we need infrastructure with adequate resources to support an AMR ecosystem that makes research and innovation an integral part of the actions taken by the government, public stakeholders, industry and end-users. Specifically, we need greater strategic funding and programs to deliver on the research strategy that the CIHR is developing. Funding for the CIHR AMR initiative is currently only at $1.8 million per year, which pales in comparison to the $21 million per year invested in the HIV/AIDS and sexually transmitted and blood-borne infections initiative, as an example.
This also means supporting programs that build partnerships between academia, industry and public-sector partners to turn discoveries into drugs and diagnostics, and knowledge into policy and intervention.
Finally, we need strong leadership that clearly understands the urgency of the AMR crisis and has a mandate to mobilize political will and resources, and a governance structure that allows coordinated actions across sectors and jurisdiction.
Thank you for your time and attention.
